Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people …

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage are …

Objective To evaluate the extent to which treatment effect on brain atrophy is able to mediate,
at the trial level, the treatment effect on disability progression in relapsing–remitting …

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-remitting,
secondary progressive, and primary progressive—for patient care, research, …

Background In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs)
affects immune response to antigens. Therefore, post-vaccination serological assessments …

For people with multiple sclerosis, the situation carries additional reasons for concern.
Although emerging work suggests that some coexisting diseases, such as hypertension, might …

Background A meta-analysis of randomised trials in relapsing-remitting multiple sclerosis
published in 2009 showed a quantitative relation between the treatment effects detected on …

Background Adjuvant chemotherapy with anthracyclines improves disease-free and overall
survival compared with non–anthracycline-based adjuvant chemotherapy regimens in the …